Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of GWP42004 added to metformin in type 2 diabetes
2013-001140-61Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tetrahydrocannabivarin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Change from baseline in HbA1c. Started Nov 2013; status: completed.
02
Drugs
tetrahydrocannabivarin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-001140-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001140-61.